Evidence map›Paper›PMID 42764717›Full record

ArticleCardiovascular therapeutics2026

Zhenwu Decoction Attenuates Water-Retention-Related Phenotypes and Multiorgan Injury in Rats With Doxorubicin-Induced Chronic Heart Failure.

Weijun Li, Zhenyu Zhao, Xuefeng Lin, Guoliang Chen, Lin Li, Ge Fang, Zhixi Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weijun LiCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.ORCID https://orcid.org/0009-0001-8567-4551
Zhenyu ZhaoCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.ORCID https://orcid.org/0000-0002-2355-6832
Xuefeng LinCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.
Guoliang ChenCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.
Lin LiCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.ORCID https://orcid.org/0000-0002-5958-0666
Ge FangHunan Traditional Chinese Medical College, Zhuzhou City, Hunan Province, China.ORCID https://orcid.org/0000-0002-6156-0947
Zhixi HuCollege of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha City, Hunan Province, China, hnctcm.edu.cn.ORCID https://orcid.org/0000-0002-2316-8645

Funding

National Natural Science Foundation of China 82305092National Natural Science Foundation of China 82574922
6 · The paper itself

Abstract

objectiveThis study is aimed at evaluating the effects of Zhenwu Decoction (ZWD) on cardiac dysfunction, water-retention-related phenotypes, and brain and kidney injury in rats with doxorubicin-induced chronic heart failure (CHF), and at examining whether these effects were accompanied by changes in AVP, V2R, PKA-Cα, and AQP2-related markers.

methodsRats that met the prespecified CHF criteria after doxorubicin administration were rerandomized to the model, ZWD-L, ZWD-M, ZWD-H, or tolvaptan groups and treated once daily for 14 consecutive days. Cardiac function, biochemical and water balance-related outcomes, histopathology, brain AVP, and renal V2R, PKA-Cα, and AQP2 expression were assessed. The animal was the experimental unit, and the number analyzed is reported for each outcome.

resultsCompared with the control group, model rats showed impaired cardiac function; increased ascites and tissue water retention; reduced 24-h urine output; histological injury in the heart, brain, and kidney; and altered AVP, V2R, PKA-Cα, and AQP2-related markers. ZWD treatment was associated with improvement in these measured outcomes, with the magnitude and statistical support varying across doses. Tolvaptan produced the expected aquaretic reference response. Adjusted p values and the number of animals analyzed are reported for each outcome.

conclusionIn this doxorubicin-induced CHF model, ZWD improved cardiac function and water-retention-related phenotypes and was accompanied by changes in AVP, V2R, PKA-Cα, and AQP2-related markers. These data support an association but do not establish pathway mediation, direct target engagement, or heart-brain-kidney crosstalk.

Indexed as

BrainDoxorubicinDrugs, Chinese HerbalHeart FailureKidneyVentricular Function, LeftWater-Electrolyte BalanceAnimalsAntidiuretic Hormone Receptor AntagonistsAquaporin 2Arginine VasopressinChronic DiseaseCyclic AMP-Dependent Protein KinasesDisease Models, AnimalMaleMyocardiumAntidiuretic Hormone Receptor AntagonistsAqp2 protein, ratAquaporin 2Arginine VasopressinCyclic AMP-Dependent Protein KinasesDoxorubicinDrugs, Chinese HerbalReceptors, VasopressinV2 vasopressin receptor, rataquaporin 2arginine vasopressinchronic heart failuredoxorubicinfluid retentionvasopressin V2 receptorZhenwu Decoction

Identifiers

PMID42764717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.